BCEL vs. PHIO, ARDS, REVB, ARAV, SXTP, PHAS, GOVX, NBY, AGRX, and RNAZ
Should you be buying Atreca stock or one of its competitors? The main competitors of Atreca include Phio Pharmaceuticals (PHIO), Aridis Pharmaceuticals (ARDS), Revelation Biosciences (REVB), Aravive (ARAV), 60 Degrees Pharmaceuticals (SXTP), PhaseBio Pharmaceuticals (PHAS), GeoVax Labs (GOVX), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical preparations" industry.
Atreca (NASDAQ:BCEL) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
37.5% of Atreca shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 11.3% of Atreca shares are held by insiders. Comparatively, 0.8% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Phio Pharmaceuticals' return on equity of -134.66% beat Atreca's return on equity.
In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Atreca. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 3 mentions for Atreca. Atreca's average media sentiment score of 0.46 beat Phio Pharmaceuticals' score of -0.42 indicating that Atreca is being referred to more favorably in the media.
Atreca received 60 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 62.50% of users gave Phio Pharmaceuticals an outperform vote.
Atreca has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Atreca presently has a consensus target price of $4.00, suggesting a potential upside of 4,605.88%. Phio Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 496.13%. Given Atreca's higher possible upside, equities analysts plainly believe Atreca is more favorable than Phio Pharmaceuticals.
Summary
Atreca beats Phio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Atreca News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
